

Celgene, Genzyme, Merck Serono, Novartis, Roche, and Teva, and receives research support from the MS Society of Canada and Fondazione Italiana Sclerosi Multipla. Dr. Kantarci reported no disclosures. Dr. Filippi reported is Editor-in-Chief of the *Journal of Neurology*, Associate Editor of *Human Brain Mapping*, Associate Editor of *Radiology*, and Associate Editor of *Neurological Sciences*; received compensation for consulting services and/or speaking activities from Alexion, Ammirall, Bayer, Biogen, Celgene, Eli Lilly, Genzyme, Merck-Serono, Novartis, Roche, Sanofi, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA).

¹Department of Neurology, Mayo Clinic, Rochester, MN

²Department of Radiology, Mayo Clinic, Rochester, MN

³Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy

⁴Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

⁵Vita-Salute San Raffaele University, Milan, Italy

⁶Neurophysiology Service, IRCCS San Raffaele Scientific Institute, Milan, Italy

⁷Neurorehabilitation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy




Address correspondence to Dr Zeydan, Mayo Clinic, Department of Neurology, 200 First Street, SW, Rochester, MN 55905, USA. E-mail: zeydan.burcu@mayo.edu






References

1. Bischof A, Papinutto N, Keshavan A, et al. Spinal cord atrophy predicts progressive disease in relapsing multiple sclerosis. *Ann Neurol* 2021;91:268-281.
2. Zeydan B, Gu X, Atkinson EJ, et al. Cervical spinal cord atrophy: an early marker of progressive MS onset. *Neurol Neuroimmunol Neuroinflamm* 2018;5:e435.
3. Rocca MA, Valsasina P, Meani A, et al. Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS. *Neurology* 2019;93:e1852-e1866.
4. Filippi M, Preziosa P, Barkhof F, et al. Diagnosis of progressive multiple sclerosis from the imaging perspective: a review. *JAMA Neurol* 2021;78:351-364.

DOI: 10.1002/ana.26341

Reply to “Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS”

Antje Bischof, MD ^{1,2}, Nico Papinutto, PhD,¹
Anisha Keshavan, PhD,¹ Anand Rajesh, BS,¹
Gina Kirkish, MS,¹ Xinheng Zhang, MS,¹
Jacob M. Mallott, MS ¹, Carlo Asteggiano, MD,¹
Simone Sacco, MD ¹, Tristan J. Gundel, BS,¹
Chao Zhao, MS,¹ William A. Stern, RT (MR),¹
Eduardo Caverzasi, MD ¹, Yifan Zhou, BA,¹

Refujia Gomez, BS,¹ Nicholas R. Ragan, BS,¹
Adam Santaniello, BSc,¹ Alyssa H. Zhu, MS,¹
Jeremy Juwono, BS,¹ Carolyn J. Bevan, MD,¹
Riley M. Bove, MD,¹ Elizabeth Crabtree-Hartman, MD,¹
Jeffrey M. Gelfand, MD,¹ Douglas S. Goodin, MD,¹
Jennifer S. Graves, MD ¹, Ari J. Green, MD,¹
Jorge R. Oksenberg, PhD,¹ Emmanuelle Waubant, MD ¹,
Michael R. Wilson, MD,¹ Scott S. Zamvil, MD ¹,
University of California, San Francisco MS-EPIC Team,¹
Bruce A. Cree, MD ¹, Stephen L. Hauser, MD ¹ and
Roland G. Henry, PhD¹

Zeydan et al underline the contribution of their work to the current knowledge of spinal cord atrophy and its usefulness as a biomarker of progressive multiple sclerosis (MS). After the early publications by Kidd and colleagues^{1,2} suggesting a strong correlation between disability and spinal cord atrophy at various cord levels in progressive MS, Filippi et al reported that cervical cord atrophy appears to be absent in benign MS but severe in secondary progressive MS (SPMS).³ Many subsequent studies confirmed and extended these findings, corroborating the role of spinal cord atrophy as a promising magnetic resonance imaging biomarker of disability and progressive disease in MS.⁴⁻¹⁰ Associations of cord atrophy with long-term disability pointed to its potential as an outcome measure in MS.¹¹ Later, evidence from longitudinally designed studies indicated that spinal cord atrophy rates were linked to disability worsening whereas baseline total cord area was not.¹² Eventually, a strong predictive value of spinal cord atrophy rates for disability worsening was shown in a mixed relapsing–remitting MS (RRMS)/SPMS cohort over 6 years by introduction of a more sophisticated statistical approach using survival analyses.¹³

In their cross-sectional study, Zeydan et al assessed total cord area shortly after SPMS conversion at the C2, C7, and C2–C7 levels from T2-weighted clinical protocols. In contrast to our study,¹⁴ they did not find differences between RRMS and SPMS patients at the high cervical cord level.¹⁵ However, cord area at the C7 level discriminated between the two groups, suggesting that caudal levels were more sensitive to disability than those in the high cervical cord, an analysis not undertaken in our study. As mentioned by the authors, this finding was confirmed and extended by Rocca et al,¹⁶ who more comprehensively assessed the entire cervical cord at each vertebral level.

However, as the authors state in their letter, they could only hypothesize on the occurrence of spinal cord atrophy during the preceding relapsing phase due to the cross-sectional nature of their study. By contrast, our study is the first to longitudinally assess patients during the preceding relapsing phase before they converted to SPMS, some as early as 12 years before conversion. This allowed us to evaluate the predictive value of brain and CIA (cervical cord area at the C1 vertebral level) measures for silent progression and SPMS conversion. Of note, this long observational period exceeds that of diagnostic uncertainty due to an insidious clinical worsening, which could have confounded the results by Zeydan et al.¹⁷ Our finding that CIA rates are predictive of SPMS is clearly novel. The result also calls into question the concept of a dichotomy between RRMS and SPMS, and suggests that a redefinition of

SPMS based on more sensitive measures including cord atrophy rates might be considered. Finally, we recently reported that spinal cord gray matter area might be an even more sensitive indicator of future outcome in MS as the total cord area can be larger in patients than controls during early disease and in those patients who do not progress clinically.^{18,19}

Potential Conflicts of Interest

The following companies that have had financial relationships with authors manufacture disease-modifying drugs for MS that were mentioned in this study: Bayer Schering, Biogen, EMD Serono, Genentech, Genzyme, F. Hoffmann-La Roche, Mylan Pharmaceuticals, Novartis, Sanofi, Teva Pharmaceuticals. R.M.B. has received personal compensation for medical legal consulting and for consulting or serving on the advisory boards of F. Hoffmann-La Roche, Sanofi-Genzyme, and Novartis. J.M.G. reports consulting fees from Biogen and research support from Genentech. D.S.G. has received research support and given lectures on MS and its treatment that have been sponsored by Biogen Idec, Bayer Schering, Novartis, EMD Serono, Genzyme, and Teva Pharmaceuticals. J.S.G. reports personal fees from Novartis and Genentech and grants from Biogen, and EMD Serono. A.J.G. reports personal fees from Mylan Pharmaceuticals, grants from Novartis, and payments for serving on committees from Biogen and Novartis. E.W. has received research support from Novartis and Roche. M.R.W. receives research support from Roche/Genentech. S.S.Z. has served as a consultant and received honoraria from Biogen Idec, EMD Serono, Genzyme, Novartis, Roche/Genentech, and Teva Pharmaceuticals, and has served on data safety monitoring boards for Teva. B.A.C. has received personal compensation for consulting from Biogen, EMD Serono, and Novartis. R.G.H. received grants from Hoffmann La Roche, and consultancy honoraria from Roche/Genentech, Sanofi/Genzyme, and Novartis. S.L.H. has received travel reimbursement and writing assistance from F. Hoffman-La Roche and Novartis Pharma. The other authors have nothing to report.

¹Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA

²Department of Neurology with Institute for Translational Neurology, University Hospital Münster, Münster, Germany

Address correspondence to Dr Bischof, Department of Neurology with Institute for Translational Neurology, University Hospital Münster, Münster, Germany. E-mail: antje.bischof@ukmuenster.de

References

- Kidd D, Thorpe JW, Thompson AJ, et al. Spinal cord MRI using multi-array coils and fast spin echo: II. Findings in multiple sclerosis. *Neurology* 1993;43:2632–2637.
- Kidd D, Thorpe JW, Kendall BE, et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. *J Neurol Neurosurg Psychiatry* 1996;60:15–19.
- Filippi M, Campi A, Colombo B, et al. A spinal cord MRI study of benign and secondary progressive multiple sclerosis. *J Neurol* 1996;243:502–505.
- Biberacher V, Boucard CC, Schmidt P, et al. Atrophy and structural variability of the upper cervical cord in early multiple sclerosis. *Mult Scler* 2015;21:875–884.
- Cawley N, Tur C, Prados F, et al. Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis. *Mult Scler* 2018;24:932–941.
- Gass A, Rocca MA, Agosta F, et al. MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis. *Lancet Neurol* 2015;14:443–454.
- Kearney H, Rocca MA, Valsasina P, et al. Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. *Mult Scler* 2014;20:72–80.
- Lycklama Nijeholt GJ, Castelijns JA, Lazeron RH, et al. Magnetization transfer ratio of the spinal cord in multiple sclerosis: relationship to atrophy and neurologic disability. *J Neuroimaging* 2000;10:67–72.
- Muccilli A, Seyman E, Oh J. Spinal cord MRI in multiple sclerosis. *Neurol Clin* 2018;36:35–57.
- Stevenson VL, Leary SM, Losseff NA, et al. Spinal cord atrophy and disability in MS: a longitudinal study. *Neurology* 1998;51:234–238.
- Rocca MA, Horsfield MA, Sala S, et al. A multicenter assessment of cervical cord atrophy among MS clinical phenotypes. *Neurology* 2011;76:2096–2102.
- Lukas C, Knol DL, Sombekke MH, et al. Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2015;86:410–418.
- Tsagkas C, Magon S, Gaetano L, et al. Spinal cord volume loss: a marker of disease progression in multiple sclerosis. *Neurology* 2018;91:e349–e358.
- Bischof A, Papinutto N, Keshavan A, et al. Spinal cord atrophy predicts progressive disease in relapsing multiple sclerosis. *Ann Neurol* 2022;91:268–281.
- Zeydan B, Gu X, Atkinson EJ, et al. Cervical spinal cord atrophy: an early marker of progressive MS onset. *Neurol Neuroimmunol Neuroinflamm* 2018;5:e435.
- Rocca MA, Valsasina P, Meani A, et al. Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS. *Neurology* 2019;93:e1852–e1866.
- Lorscheider J, Buzzard K, Jokubaitis V, et al. Defining secondary progressive multiple sclerosis. *Brain* 2016;139:2395–2405.
- Schlaeger R, Papinutto N, Panara V, et al. Spinal cord gray matter atrophy correlates with multiple sclerosis disability. *Ann Neurol* 2014;76:568–580.
- Schlaeger R, Papinutto N, Zhu AH, et al. Association between thoracic spinal cord gray matter atrophy and disability in multiple sclerosis. *JAMA Neurol.* 2015;72(8):897–904. doi:10.1001/jamaneurol.2015.0993

DOI: 10.1002/ana.26340